Changing from NAFLD to MASLD: The implications for health-related quality of life data [0.03%]
从NAFLD转变为MASLD与健康相关的生活质量数据的含义
Ryuki Hashida,Dan Nakano,Machiko Kawaguchi et al.
Ryuki Hashida et al.
Comment on "Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany" [0.03%]
对“基于人群的筛查有效：将乙型和丙型肝炎筛查整合到德国普通健康体检中的效果”的评论
Renke Biallas,Ruth Zimmermann,Sandra Dudareva
Renke Biallas
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma [0.03%]
CRKL通过介导肝细胞癌中肿瘤相关中性粒细胞的浸润来决定抗PD-1耐药性
Peiyi Xie,Mincheng Yu,Bo Zhang et al.
Peiyi Xie et al.
Background & aims: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain e...
Potential augmentation of terlipressin antidiuretic effects by gabapentinoids [0.03%]
加巴喷丁类药物可能增强特利加压素的抗利尿作用
Penelope N Markham,Jasmohan S Bajaj,Paul J Thuluvath et al.
Penelope N Markham et al.
Sarah Haxhe,Pamela Baldin,Pierre Trefois et al.
Sarah Haxhe et al.
From the Editor's Desk. [0.03%]
主编案头工作。
Patrizia Burra,Frank Tacke,Vlad Ratziu et al.
Patrizia Burra et al.
Josef Blaszkiewicz,Stephen A Duncan
Josef Blaszkiewicz
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models [0.03%]
使用三维细胞外基质模型探索PNPLA3 I148M变异在原代人肝星状细胞上的影响
Elisabetta Caon,Maria Martins,Harry Hodgetts et al.
Elisabetta Caon et al.
Background & aims: The PNPLA3 rs738409 C>G (encoding for I148M) variant is a risk locus for the fibrogenic progression of chronic liver diseases, a process driven by hepatic stellate cells (HSCs). We investigated how the ...
Reply to: "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?" [0.03%]
经颈静脉肝内门体分流术后肝性脑病和生存率：自发性门体分流有影响吗？
Silvia Nardelli,Filippo Schepis,Francesco Vizzutti
Silvia Nardelli